Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
ID: 331379Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/331379

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-115.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at advancing research on disorders identifiable through newborn screening. This initiative encourages applications that propose comprehensive studies to enhance understanding of these disorders, which is crucial for timely interventions for affected infants. The funding seeks to bridge knowledge gaps in newborn screening practices, ultimately improving diagnosis, treatment, and support for families, with no budget limits but a maximum project duration of five years. Interested applicants, including a diverse range of organizations such as higher education institutions and nonprofit entities, must submit their proposals by January 7, 2025, and can find additional information at NIH Grants.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-115-Full-Announcement.html
    PAR-21-115.html
    The Department of Health and Human Services (HHS), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), announces the funding opportunity for research projects that explore the natural history of disorders identifiable through newborn screening. The goal is to develop comprehensive studies leading to improved understanding of these disorders, which will facilitate timely interventions for affected infants. The announcement invites applications that either enhance existing knowledge of currently screened disorders or investigate new conditions that could benefit from screening, emphasizing partnerships across multiple states for broader data collection. Eligible applicants include a wide array of organizations, from higher education institutions to nonprofit organizations and government entities. There are no budget limits, but proposals should reflect actual project needs, with a maximum project duration of five years. The initiative aligns with legislative goals to improve newborn screening practices and public health outcomes. Applications are subject to rigorous peer review based on significance, innovation, approach, and investigator qualifications. This funding opportunity aims to bridge knowledge gaps in newborn screening, ultimately improving diagnosis, treatment, and support for affected families.
    Similar Opportunities
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R03 Small Grant Program to enhance clinical trial readiness for rare diseases, disorders, and syndromes. This initiative aims to support research that identifies critical needs for advancing therapeutics or diagnostics in rare diseases, which are defined as affecting fewer than 200,000 individuals in the U.S., by developing better biomarkers, clinical outcome measures, and insights into the natural history of these conditions. The program emphasizes the importance of partnerships among researchers, industry, and patient advocacy groups to optimize clinical trial designs, while explicitly stating that applications should not propose clinical trials directly but focus on pre-trial research activities. The maximum funding available for each project is $100,000 over a two-year period, with applications due by October 17, 2024. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-160.html.
    Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Project Grant (Parent R01 Clinical Trial Required) to support specified clinical research projects that align with the missions of various NIH institutes. Applicants are required to propose at least one clinical trial, focusing on significant health-related research areas, and must comply with the NIH Grants Policy Statement. This funding opportunity is crucial for advancing medical science and improving patient care, emphasizing innovation and scientific merit in addressing important health issues. The application deadline is January 7, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-20-183.html.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (U01), aimed at supporting Investigational New Drug (IND)-enabling studies and clinical trial planning for innovative gene-based therapeutics targeting ultra-rare diseases affecting fewer than 6,000 individuals. The program seeks to advance promising therapeutic candidates through robust proof-of-concept data and facilitate the submission of IND applications to the FDA, thereby addressing significant unmet medical needs within the ultra-rare disease community. Eligible applicants include higher education institutions, nonprofits, and governmental agencies, with a project period not exceeding two years and application deadlines ranging from October 2023 to February 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided NIH link.
    Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)" aimed at supporting research into the connections between brain circuit maturation and behavioral development in rodents and non-human primates. This initiative seeks to explore how neural interactions evolve during pre- and post-natal development, influencing cognitive, emotional, and social behaviors, with a focus on in vivo neural measures and developmental trajectories from prenatal stages to early adulthood. Grants of up to $500,000 per year are available for a maximum duration of five years, with applications due by January 7, 2025. Interested applicants can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and detailed guidelines are available at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-066.html.